antimicrobial-resistance
(3)
Niamh O'Hara
Niamh O'Hara is the co-founder and CEO of Biotia, a New York healthtech company that pairs next-generation DNA sequencing with AI to identify pathogens causing hard-to-diagnose infections. An evolutionary biologist by training, she spun the company out of Cornell Tech with Weill Cornell geneticist Christopher Mason, runs a CLIA-certified metagenomics lab in Long Island City, and is building what she calls a global microbial sequence database to catch outbreaks before they spread.
Alec Ford
Alec Ford is the chief executive of Karius, a Redwood City genomics-diagnostics company that reads microbial cell-free DNA from a single tube of blood to identify more than a thousand pathogens. He took the job in October 2020 and led the company through a $100M Series C in May 2024.
Vishwanath Lingappa
Vishwanath Lingappa is the CEO and CTO of Prosetta Biosciences, a San Francisco-based biotechnology company he founded in 2003 after 22 years as a faculty member at UCSF. An MD-PhD with a doctorate from The Rockefeller University under Nobel laureate Gunter Blobel, Lingappa developed a proprietary Cell-Free Protein Synthesis System (CFPSS) drug discovery platform that targets transient multi-protein complexes - a class of drug targets largely ignored by traditional pharma. His company is pursuing small-molecule therapeutics across neurodegenerative diseases (Alzheimer's, ALS, Parkinson's), oncology, and infectious diseases (COVID-19, HIV, influenza), and won an ARPA-H Dash competition for a pan-cancer drug candidate. With over 157 publications and 12,800+ citations, Lingappa bridges rigorous academia with commercial biotech ambition.